SanBio Company Limited
OTC: SNBIF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Keita Mori
- Employees
- 29
- Headquarters
- Tokyo, Japan
- IPO year
- 2015
- Market cap
- $1.3B
- Website
- https://www.sanbio.jp
Loading SNBIF…
Loading profile data…Frequently asked questions about SNBIF
What does SanBio Company Limited (SNBIF) do?
SanBio Company Limited is a biopharmaceutical firm specializing in the development, manufacture, and commercialization of regenerative cell therapies, with a primary focus on disorders of the central nervous system. A significant product in its portfolio is SB623, which has successfully completed Phase 2 clinical trials in both the United States...
Where does SNBIF trade?
SanBio Company Limited (SNBIF) trades on the Other OTC.
What sector is SNBIF in?
SanBio Company Limited (SNBIF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of SanBio Company Limited?
Keita Mori is the chief executive officer of SanBio Company Limited (SNBIF).
Where is SanBio Company Limited headquartered?
SanBio Company Limited is headquartered in Japan.
Does SNBIF pay a dividend?
SanBio Company Limited (SNBIF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SNBIF go public?
SanBio Company Limited (SNBIF) completed its initial public offering in 2015.